Cargando…

Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

BACKGROUND: Despite extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), most patients with resectable peritoneal metastases from colorectal cancer experience disease relapse. MOC31PE immunotoxin is being explored as a novel treatment option for these patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Thorgersen, Ebbe Billmann, Asvall, Jørund, Frøysnes, Ida Storhaug, Schjalm, Camilla, Larsen, Stein Gunnar, Dueland, Svein, Andersson, Yvonne, Fodstad, Øystein, Mollnes, Tom Eirik, Flatmark, Kjersti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349350/
https://www.ncbi.nlm.nih.gov/pubmed/34019185
http://dx.doi.org/10.1245/s10434-021-10022-0
_version_ 1783735550614700032
author Thorgersen, Ebbe Billmann
Asvall, Jørund
Frøysnes, Ida Storhaug
Schjalm, Camilla
Larsen, Stein Gunnar
Dueland, Svein
Andersson, Yvonne
Fodstad, Øystein
Mollnes, Tom Eirik
Flatmark, Kjersti
author_facet Thorgersen, Ebbe Billmann
Asvall, Jørund
Frøysnes, Ida Storhaug
Schjalm, Camilla
Larsen, Stein Gunnar
Dueland, Svein
Andersson, Yvonne
Fodstad, Øystein
Mollnes, Tom Eirik
Flatmark, Kjersti
author_sort Thorgersen, Ebbe Billmann
collection PubMed
description BACKGROUND: Despite extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), most patients with resectable peritoneal metastases from colorectal cancer experience disease relapse. MOC31PE immunotoxin is being explored as a novel treatment option for these patients. MOC31PE targets the cancer-associated epithelial cell adhesion molecule, and kills cancer cells by distinct mechanisms, simultaneously causing immune activation by induction of immunogenic cell death (ICD). METHODS: Systemic and local cytokine responses were analyzed in serum and intraperitoneal fluid samples collected the first three postoperative days from clinically comparable patients undergoing CRS-HIPEC with (n = 12) or without (n = 26) intraperitoneal instillation of MOC31PE. A broad panel of 27 pro- and antiinflammatory interleukins, chemokines, interferons, and growth factors was analyzed using multiplex technology. RESULTS: The time course and magnitude of the systemic and local postoperative cytokine response after CRS-HIPEC were highly compartmentalized, with modest systemic responses contrasting substantial intraperitoneal responses. Administration of MOC31PE resulted in changes that were broader and of higher magnitude compared with CRS-HIPEC alone. Significantly increased levels of innate proinflammatory cytokines, such as interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF) as well as an interesting time response curve for the strong T-cell stimulator interferon (IFN)-γ and its associated chemokine interferon gamma-induced protein/chemokine (C-X-C motif) ligand 10 (IP-10) were detected, all associated with ICD. CONCLUSIONS: Our study revealed a predominately local rather than systemic inflammatory response to CRS-HIPEC, which was strongly enhanced by MOC31PE treatment. The MOC31PE-induced intraperitoneal inflammatory reaction could contribute to improve remnant cancer cell killing, but the mechanisms remain to be elucidated in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-021-10022-0.
format Online
Article
Text
id pubmed-8349350
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83493502021-08-20 Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Thorgersen, Ebbe Billmann Asvall, Jørund Frøysnes, Ida Storhaug Schjalm, Camilla Larsen, Stein Gunnar Dueland, Svein Andersson, Yvonne Fodstad, Øystein Mollnes, Tom Eirik Flatmark, Kjersti Ann Surg Oncol Peritoneal Surface Malignancy BACKGROUND: Despite extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), most patients with resectable peritoneal metastases from colorectal cancer experience disease relapse. MOC31PE immunotoxin is being explored as a novel treatment option for these patients. MOC31PE targets the cancer-associated epithelial cell adhesion molecule, and kills cancer cells by distinct mechanisms, simultaneously causing immune activation by induction of immunogenic cell death (ICD). METHODS: Systemic and local cytokine responses were analyzed in serum and intraperitoneal fluid samples collected the first three postoperative days from clinically comparable patients undergoing CRS-HIPEC with (n = 12) or without (n = 26) intraperitoneal instillation of MOC31PE. A broad panel of 27 pro- and antiinflammatory interleukins, chemokines, interferons, and growth factors was analyzed using multiplex technology. RESULTS: The time course and magnitude of the systemic and local postoperative cytokine response after CRS-HIPEC were highly compartmentalized, with modest systemic responses contrasting substantial intraperitoneal responses. Administration of MOC31PE resulted in changes that were broader and of higher magnitude compared with CRS-HIPEC alone. Significantly increased levels of innate proinflammatory cytokines, such as interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF) as well as an interesting time response curve for the strong T-cell stimulator interferon (IFN)-γ and its associated chemokine interferon gamma-induced protein/chemokine (C-X-C motif) ligand 10 (IP-10) were detected, all associated with ICD. CONCLUSIONS: Our study revealed a predominately local rather than systemic inflammatory response to CRS-HIPEC, which was strongly enhanced by MOC31PE treatment. The MOC31PE-induced intraperitoneal inflammatory reaction could contribute to improve remnant cancer cell killing, but the mechanisms remain to be elucidated in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-021-10022-0. Springer International Publishing 2021-05-21 2021 /pmc/articles/PMC8349350/ /pubmed/34019185 http://dx.doi.org/10.1245/s10434-021-10022-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Peritoneal Surface Malignancy
Thorgersen, Ebbe Billmann
Asvall, Jørund
Frøysnes, Ida Storhaug
Schjalm, Camilla
Larsen, Stein Gunnar
Dueland, Svein
Andersson, Yvonne
Fodstad, Øystein
Mollnes, Tom Eirik
Flatmark, Kjersti
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
title Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
title_full Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
title_fullStr Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
title_full_unstemmed Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
title_short Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
title_sort increased local inflammatory response to moc31pe immunotoxin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
topic Peritoneal Surface Malignancy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349350/
https://www.ncbi.nlm.nih.gov/pubmed/34019185
http://dx.doi.org/10.1245/s10434-021-10022-0
work_keys_str_mv AT thorgersenebbebillmann increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT asvalljørund increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT frøysnesidastorhaug increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT schjalmcamilla increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT larsensteingunnar increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT duelandsvein increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT anderssonyvonne increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT fodstadøystein increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT mollnestomeirik increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy
AT flatmarkkjersti increasedlocalinflammatoryresponsetomoc31peimmunotoxinaftercytoreductivesurgeryandhyperthermicintraperitonealchemotherapy